Alector (NASDAQ:ALEC) Trading Up 6.3%

Alector, Inc. (NASDAQ:ALEC)’s share price was up 6.3% on Friday . The company traded as high as $5.79 and last traded at $5.75. Approximately 114,504 shares traded hands during trading, a decline of 83% from the average daily volume of 657,007 shares. The stock had previously closed at $5.41.

Analyst Ratings Changes

ALEC has been the subject of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Alector in a research report on Thursday, June 20th. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Alector in a report on Thursday, June 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $14.00.

Alector Stock Performance

The company has a 50 day moving average of $4.86 and a 200 day moving average of $5.85. The stock has a market capitalization of $534.00 million, a price-to-earnings ratio of -4.14 and a beta of 0.73.

Alector (NASDAQ:ALEC) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.10. The company had revenue of $15.89 million during the quarter, compared to analysts’ expectations of $14.63 million. Alector had a negative net margin of 125.11% and a negative return on equity of 71.80%. On average, equities analysts predict that Alector, Inc. will post -1.93 EPS for the current fiscal year.

Insider Buying and Selling at Alector

In related news, CEO Arnon Rosenthal sold 25,135 shares of Alector stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $4.80, for a total value of $120,648.00. Following the completion of the sale, the chief executive officer now owns 1,975,245 shares in the company, valued at approximately $9,481,176. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Arnon Rosenthal sold 25,135 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $4.80, for a total transaction of $120,648.00. Following the transaction, the chief executive officer now owns 1,975,245 shares of the company’s stock, valued at approximately $9,481,176. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Marc Grasso sold 6,920 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $4.80, for a total value of $33,216.00. Following the transaction, the chief financial officer now owns 138,037 shares of the company’s stock, valued at $662,577.60. The disclosure for this sale can be found here. Insiders have sold 40,095 shares of company stock valued at $192,456 over the last 90 days. 9.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Alector

Several large investors have recently added to or reduced their stakes in ALEC. Allspring Global Investments Holdings LLC acquired a new position in shares of Alector in the first quarter worth $40,000. China Universal Asset Management Co. Ltd. raised its position in Alector by 352.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,733 shares of the company’s stock valued at $78,000 after purchasing an additional 7,584 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in Alector in the 1st quarter valued at about $59,000. E Fund Management Co. Ltd. purchased a new position in shares of Alector in the 4th quarter valued at about $81,000. Finally, Diversified Trust Co lifted its stake in Alector by 12.3% in the fourth quarter. Diversified Trust Co now owns 14,102 shares of the company’s stock worth $113,000 after acquiring an additional 1,541 shares during the last quarter. 85.83% of the stock is owned by hedge funds and other institutional investors.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.